Brokers initiated coverage on Neumora Therapeutics and gave the stock a buy rating. The positive sentiment on the stock is largely based on the promising outlook surrounding its drug navacaprant.
Broker BofA raised its price target on Eli Lilly on promising prospects surrounding the company’s obesity treatment drug. After the increase, LLY’s share price surged 2.3%, ending trade at US$565.22 on Friday.
Broker RBC initiated coverage on Johnson & Johnson, stating that JNJ’s current trading levels is in line with historical multiples. The broker also gave JNJ a price target of US$178.
Broker UBS raised its price target on Flour Corporation as it believes that Flour’s potential has been underappreciated by investors. The broker also raised the rating on FLR from ‘neutral’ to ‘buy’.
Broker BMO lifted its price target on drugmaker Structure Therapeutics (NASDAQ: GPCR). The stock has a mean recommendation rating of 1.4 on a scale of one to five. The consensus mean price target is US$81.80.
Broker J.P. Morgan raised its rating and price target on REIT firm DigitalBridge (NYSE: DRBG). The stock has a mean recommendation rating of 1.9 on a scale of one to five. The consensus mean price target is US$21.61.
Broker BTIG raised its price target on Hudson Pacific as the resolution of the ongoing actors’ strike is expected to draw in demand recovery for HPP’s studio business. After the increase, HPP’s share price surged 2.1% on September 26, 2023.
Brokers raise their price targets on FedEx as the company gains consumers from rival firms’ recent business slowdown. After this update, FDX’s share price surged 2.63% to US$267.97 on September 25, 2023.
Brokers BTIG, Needham and Stifel Nicolaus and Company raised their price targets on BSX. Boston Scientific expects sales in Q3 2023 to be 8.5% to 10.5% higher than that in Q3 2022.
Broker Mizuho upgraded food delivery firm DoorDash (NYSE: DASH) to ‘buy’ and raised its price target on DASH to US$105. The upgrade led to the company’s stock price rising by 2% on September 18, 2023.